A5005526813- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Blood Pressure and Hypertension Studies
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Lung Cancer Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Hemodynamic Monitoring and Therapy
- Radiopharmaceutical Chemistry and Applications
- Immunotherapy and Immune Responses
- Peptidase Inhibition and Analysis
- Bladder and Urothelial Cancer Treatments
- Cancer, Hypoxia, and Metabolism
- Nutritional Studies and Diet
- Epigenetics and DNA Methylation
- Prostate Cancer Treatment and Research
- Histone Deacetylase Inhibitors Research
- Cancer Mechanisms and Therapy
- CAR-T cell therapy research
- Hepatocellular Carcinoma Treatment and Prognosis
- PI3K/AKT/mTOR signaling in cancer
Institut Català d'Oncologia
2016-2025
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2020-2025
Althaia
2024
Institut Català d'Ornitologia
2020-2024
Barcelona Graduate School of Mathematics
2023
Universitat Politècnica de Catalunya
2023
Hospital Universitari Germans Trias i Pujol
2019-2021
Institut d'Investigació Biomédica de Bellvitge
2018-2020
Universitat de Barcelona
2015
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2015
Abstract Background Standard treatment for glioblastoma is radiation with concomitant and adjuvant temozolomide 6 cycles, although the optimal number of cycles has long been a subject debate. We performed phase II randomized trial investigating whether extending more than improved outcome. Methods Glioblastoma patients treated at 20 Spanish hospitals who had not progressed after were centrally to stop (control arm) or continue (experimental up total 12 same doses they receiving in cycle 6....
Oncolytic viruses represent a unique type of agents that combine self-amplification, lytic, and immunostimulatory properties against tumors. A local locoregional clinical benefit has been demonstrated upon intratumoral injections an oncolytic herpes virus in melanoma patients, leading to its approval the United States Europe for patients without visceral disease (up stage IVM1a). However, order debulk change immunosuppressive environment tumors cannot be injected directly, oncolyitc need...
We explored the rationale for treating glioblastoma (GBM) with regorafenib. In 103 newly diagnosed GBM patients, we assessed mutations, copy number variants (CNVs), fusions, and overexpression in 46 genes encoding protein kinases (PKs) potentially targeted by regorafenib or its metabolites performed a functional enrichment analysis to assess their implications angiogenesis. analyzed regorafenib’s binding inhibitory activity target affinity these PKs focused on subset of 18 inhibited at...
Background Small-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological clinical information of SCLC patients retrieved from registries scarce. Patients methods This was observational multicenter study that enrolled thoracic tumors, recruited August 2016 January 2020 at 50 Spanish hospitals. Demographic data, treatment patterns survival included in the Thoracic Tumor Registry (TTR) were analyzed. Results...
Abstract Circulating biomarkers in blood may provide an interesting alternative to risky tissue biopsies the diagnosis and follow-up of glioblastoma patients. We have assessed MGMT methylation status samples from unresected patients who had been included randomized GENOM-009 trial. Paired were by methylation-specific PCR (MSP) pyrosequencing (PYR). After establishing minimum PYR cut-off that could yield a significant difference overall survival, we sensitivity, specificity, positive...
Immune-oncology agents (IOA) represent a turning point in the treatment of several solid tumors (ST). Although their toxicity compares favorably with other treatments, IOA associate immune-related adverse events (IR-AE), among which endocrine-related AE stand out. We retrospectively evaluated occurrence endocrine (E) IR-AE cohort patients ST treated IOA. In addition, we assessed correlation between likelihood survival and IR-AE.We collected data on clinical molecular characteristics,...
// Marta Domènech 1 , 3 Ana M. Muñoz Marmol 2 Jose Luis Mate Anna Estival Teresa Moran Marc Cucurull Maria Saigi Ainhoa Hernandez Carolina Sanz Alba Hernandez-Gallego Aintzane Urbizu Martinez-Cardus Adrià Bernat and Enric Carcereny Medical Oncology Department, Catalan Institute of Badalona, Germans Trias i Pujol Hospital, Barcelona, Spain Pathology Badalona Applied Research Group in (BARGO), Institut d'Investigació en Ciències de la Salut (IGTP),...
EORTC-1506-STBSG was a prospective, multicentric, randomised, open-label phase 2 trial to assess the efficacy and safety of second-line nintedanib versus ifosfamide in patients with advanced, inoperable metastatic soft tissue sarcoma (STS). The primary end-point progression-free survival.Patients variety STS subtypes were randomised 1:1 (200 mg b.i.d. p.o. until disease progression) or (3 g/m2 i.v. days 1-3, every 21 for ≤6 cycles). A Korn design applied aiming detect an improvement median...
The aim of this study was to determine how TERTp mutations impact glioblastoma prognosis. Materials and Methods: were assessed in a retrospective cohort 258 uniformly treated patients. RNA-sequencing whole exome sequencing results available subset Results: Overall, there no differences outcomes between patients with mutated TERTp-wt or TERTp. However, we found significant according the type mutation. Progression-free survival (mPFS) 9.1 months for those C250T mutation 7 either C228T (p =...
Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter tumor immune microenvironment. In this retrospective study, we examined 103 patients KRAS-mutant adenocarcinoma who were treated immunotherapy-based regimens and evaluated clinical outcomes according PD-L1 expression type KRAS mutation. Among all included, 47% carried G12C mutation whereas 53% harbored non-G12C mutations. status was available for 77% cases, higher among tumors...
Glioblastoma is the most aggressive brain tumor in adults and has few therapeutic options. The study of molecular subtype classifications may lead to improved prognostic classification identification new targets. Cancer Genome Atlas (TCGA) mainly been applied U.S. clinical trials, while intrinsic glioma (IGS) European trials.From paraffin-embedded samples 432 patients with uniformly treated, newly diagnosed glioblastoma, we built tissue microarrays for IHC analysis RNA sequencing best...
The significance of upfront systemic therapies as an alternative to whole brain radiotherapy (WBRT) for multiple metastases (BM) is debatable. Our purpose investigate if peritumoral edema could predict the intracranial response chemotherapy (chemo) in patients with advanced non-squamous non-small cell lung cancer (non-SQ-NSCLC) and synchronous BM.In this observational cohort study, we evaluated outcome 28 BM (≥3) treated chemo based on cisplatin/carboplatin plus pemetrexed (chemo, group A,...
10630 Background: Patients with early onset lung cancer might be more likely to carry pathogenic (or likely-pathogenic) germline variants (PGV) in genes associated predisposition. However, testing is not recommended this population. We designed study determine the prevalence of PGVs patients cancer. Methods: This prospective, multicenter cohort assessed PGV younger than 51 years diagnosed non-small cell (NSCLC) 3 sites at Catalan Institute Oncology between June 2018 May 2022. Genomic DNA was...
Abstract RNA-Sequencing (RNA-Seq) can identify gene fusions in tumors, but not all these have functional consequences. Using multiple data bases, we performed an silico analysis of detected by RNA-Seq tumor samples from 139 newly diagnosed glioblastoma patients to in-frame with predictable oncogenic potential. Among 61 fusions, there were 103 different involving 167 genes, including 20 known oncogenes or suppressor genes (TSGs), 16 associated cancer TSGs, and 32 previously shown be involved...
Abstract: Alternative dosage regimens for some anticancer therapies have been proposed in the midst of SARS-COV-2 pandemic order to protect patients from attending health care facilities. Flat-dosing several immune-checkpoint inhibitors (ICIs), including nivolumab, established. Although generally well tolerated with no new safety signals, dosages can associate novel individual toxicities. As use ICIs is increasing cancer patients, present case report a reminder clinicians potential...